TriangleNCT02102490 · OUTCOME
Overall Survival (OS)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- Months
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- From Date of First Dose until Death Due to Any Cause (Up To 27 Months)
What was measured
OS defined as the time from first dose date to the date of death due to any cause. For each participant who is not known to have died as of the data-inclusion cutoff date for overall survival analysis, OS time was censored on the last date the participant is known to be alive.
Analysis population: All enrolled participants who received at least one dose of study drug. Censored participants: Abemaciclib=70.
Groups in this outcome
Abemaciclib
200 mg abemaciclib given orally once every 12 hours for 28 days (1 cycle). Participants may continue to receive treatment until discontinuation criteria are met.
| Group | Source count |
|---|---|
| Abemaciclib | 132 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Abemaciclib | 22.32 | Not reported | 17.72 | NA | The upper limit of the 95% confidence interval (CI) was not calculated due to the high censoring rate. |
Complete source fields
- classes
- categories
- measurements
- comment
- The upper limit of the 95% confidence interval (CI) was not calculated due to the high censoring rate.
- group Id
- OG000
- lower Limit
- 17.72
- upper Limit
- NA
- value
- 22.32
- denoms
- counts
- group Id
- OG000
- value
- 132
- units
- Participants
- description
- OS defined as the time from first dose date to the date of death due to any cause. For each participant who is not known to have died as of the data-inclusion cutoff date for overall survival analysis, OS time was censored on the last date the participant is known to be alive.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- 200 mg abemaciclib given orally once every 12 hours for 28 days (1 cycle). Participants may continue to receive treatment until discontinuation criteria are met.
- id
- OG000
- title
- Abemaciclib
- param Type
- MEDIAN
- population Description
- All enrolled participants who received at least one dose of study drug. Censored participants: Abemaciclib=70.
- reporting Status
- POSTED
- time Frame
- From Date of First Dose until Death Due to Any Cause (Up To 27 Months)
- title
- Overall Survival (OS)
- type
- SECONDARY
- unit Of Measure
- Months
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice